A new long-lasting treatment to prevent HIV infection
Official title: XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies
Funded at Exavir Therapeutics INC. · NIH-10909311 · Data updated 2026-11-12
This study is testing a new long-lasting injection to help prevent HIV in people at risk, making it easier for them to stay protected without needing to visit the clinic as often.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Exavir Therapeutics INC. NIH-funded |
| Lab location | 1 site (San Francisco, UNITED STATES) |
| Project start | August 17, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,000,000 |
| NIH project number | 5R44AI179564-02 |
| Project ID | NIH-10909311 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults and adolescents over 21 years old who are at high risk of acquiring HIV.
✕Less likely to help
Patients who are not at risk for HIV or those who are already living with HIV may not benefit from this research.
What this research studies
This research focuses on developing an ultra-long-acting injectable medication for HIV pre-exposure prophylaxis (PrEP) to help prevent HIV infections in at-risk populations. The approach aims to improve adherence to treatment by extending the time between doses, which could reduce the need for frequent clinic visits. By using a nanoformulated prodrug, the study seeks to enhance the effectiveness of current prevention strategies and minimize the risk of drug resistance. Patients will be monitored for safety and efficacy during the trial.
Why it matters
Potential benefit: If successful, this research could significantly reduce the rate of new HIV infections among at-risk individuals.
How similar studies have gone: Other research has shown promise with long-acting antiretroviral therapies, indicating potential for success with this novel approach.
Where this research is happening
-
Exavir Therapeutics INC.
San Francisco, United States Active
Researchers
- Principal investigator: Kearney, Brian — Exavir Therapeutics INC.
- Study coordinator: Kearney, Brian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.